However, always consult your healthcare provider before making any changes to your treatment regimen, as your medical history and other medications may affect the switching protocol
The most common side effects were mild to moderate gastrointestinal issues, with about one-third of patients on the highest orforglipron dose experiencing nausea and about one-quarter experiencing constipation or diarrhea
Tirzepatide: A dual GLP-1 and GIP receptor agonist, Tirzepatide not only helps control appetite but also enhances insulin sensitivity and fat metabolism
Despite being identified as a promising candidate in 1998, ipamorelin never advanced through full clinical development
The results were expressed as the hemocompatibility percentage, obtained from the equation below: Where Dt = absorbance of the test sample
NICE guidance recommends formal assessment at six months, with continuation criteria including HbA1c reduction of at least 11 mmol/mol and weight loss of at least 3% where applicable